de Barra Mícheál, Scott Claire, Johnston Marie, De Bruin M, Scott Neil, Matheson Catriona, Bond Christine, Watson Margaret
Life Sciences, Brunel University London, Middlesex, UK
The Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
BMJ Open. 2019 Dec 19;9(12):e025511. doi: 10.1136/bmjopen-2018-025511.
Scientific progress and translation of evidence into practice is impeded by poorly described interventions. The Template for Intervention Description and Replication (TIDieR) was developed to specify the minimal intervention elements that should be reported.
(1) To assess the extent to which outpatient pharmacy interventions were adequately reported. (2) To examine the dimension(s) across which reporting quality varies. (3) To examine trial characteristics that predict better reporting.
The sample comprised 86 randomised controlled trials identified in a Cochrane review of the effectiveness of pharmacist interventions on patient health outcomes. Duplicate, independent application of a modified 15-item TIDieR checklist was undertaken to assess the intervention reporting. The reporting/non-reporting of TIDieR items was analysed with principal component analysis to evaluate the dimensionality of reporting quality and regression analyses to assess predictors of reporting quality RESULTS: In total, 422 (40%) TIDieR items were fully reported, 395 (38%) were partially reported and 231 (22%) were not reported. A further 242 items were deemed not applicable to the specific trials. Reporting quality loaded on one component which accounted for 26% of the variance in TIDieR scores. More recent trials reported a slightly greater number of TIDieR items (0.07 (95% CI 0.02 to 0.13) additional TIDieR items per year of publication). Trials reported an 0.09 (95% CI 0.04 to 0.14) additional TIDieR items per unit increase in impact factor (IF) of the journal in which the main report was published.
Most trials lacked adequate intervention reporting. This diminished the applied and scientific value of their research. The standard of intervention reporting is, however, gradually increasing and appears somewhat better in journals with higher IFs. The use of the TIDieR checklist to improve reporting could enhance the utility and replicability of trials, and reduce research waste.
干预措施描述不当会阻碍科学进步以及将证据转化为实践。干预描述与复制模板（TIDieR）旨在明确应报告的最小干预要素。
（1）评估门诊药房干预措施的报告充分程度。（2）检查报告质量存在差异的维度。（3）检查预测报告质量更佳的试验特征。
样本包括在Cochrane系统评价中确定的86项随机对照试验，该评价涉及药剂师干预对患者健康结局的有效性。采用修改后的15项TIDieR清单进行重复、独立应用，以评估干预措施报告情况。通过主成分分析对TIDieR项目的报告/未报告情况进行分析，以评估报告质量的维度，并通过回归分析评估报告质量的预测因素。结果：总共，422项（40%）TIDieR项目得到充分报告，395项（38%）部分报告，231项（22%）未报告。另有242项被认为不适用于特定试验。报告质量在一个成分上有载荷，该成分占TIDieR分数方差的26%。较新的试验报告的TIDieR项目数量略多（每年发表的试验额外报告0.07项（95%置信区间0.02至0.13）TIDieR项目）。主要报告发表的期刊影响因子每增加一个单位，试验报告的TIDieR项目就额外增加0.09项（95%置信区间0.04至0.14）。
大多数试验缺乏充分的干预措施报告。这降低了其研究的应用价值和科学价值。然而，干预措施报告的标准正在逐渐提高，在影响因子较高的期刊中似乎略好一些。使用TIDieR清单来改善报告情况可以提高试验的实用性和可重复性，并减少研究浪费。
